Private Placements, Capital Formation,
Restructuring & Recapitalizations



MGI Pharma, Inc. ~ 4,400,000 Shares ~ August 2003

MGI Pharma, Inc. (Nasdaq: MOGN), is an oncology-focused biopharmaceutical company that acquires, develops and commercializes proprietary pharmaceutical products. Since 1996, Taglich Brothers has followed the Company when it had a market capitalization of less than $65 Million. Today, MGI Pharma is an emerging player in the oncology space with a market capitalization close to $1 Billion. Participating in this offering is just one example of how Taglich Brothers is committed to a company, even when they out-grow our microcap specialization.

The information contained herein does not constitute a solicitation of any order to buy or sell any securities. The information provided herein may be displayed and printed for your personal, noncommercial use only. You may not reproduce, retransmit, distribute, disseminate, sell, publish, broadcast or circulate the information to anyone, without the express written consent of Taglich Brothers, Inc.